Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) Latest Advances

Find the Latest Research About Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 472 publications

Navigating murky waters: risk scores for nodular lymphocyte-predominant Hodgkin lymphoma.

Navigating murky waters: risk scores for nodular lymphocyte-predominant Hodgkin lymphoma.

Journal: Haematologica

Published: August 03, 2026

Glowing evidence: radiation shines in early NLPHL.

Glowing evidence: radiation shines in early NLPHL.

Journal: Blood advances

Published: July 31, 2026

From Unicentric Castleman Disease to Lymphoma: A Rare Case Highlighting a Diagnostic and Therapeutic Challenge.

From Unicentric Castleman Disease to Lymphoma: A Rare Case Highlighting a Diagnostic and Therapeutic Challenge.

Journal: Cureus

Published: May 25, 2026

Treatment outcomes of Hodgkin lymphoma in the Czech Republic.

Treatment outcomes of Hodgkin lymphoma in the Czech Republic.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: May 22, 2026

Prognostic impact of presentation phenotypes in early-stage favorable Hodgkin lymphoma.

Prognostic impact of presentation phenotypes in early-stage favorable Hodgkin lymphoma.

Journal: Cancer

Published: March 21, 2026

Utility of ultrasensitive, US Food and Drug Administration-approved κ and λ dual in situ hybridization assay in the diagnosis of Hodgkin lymphomas.

Utility of ultrasensitive, US Food and Drug Administration-approved κ and λ dual in situ hybridization assay in the diagnosis of Hodgkin lymphomas.

Journal: American journal of clinical pathology

Published: March 05, 2026

Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report.

Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report.

Journal: Leukemia

Published: March 02, 2026

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Journal: Blood advances

Published: February 05, 2026

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Journal: Blood advances

Published: February 05, 2026

Comparison and combination of prognostic scores for nodular lymphocytepredominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.

Comparison and combination of prognostic scores for nodular lymphocytepredominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.

Journal: Haematologica

Published: January 29, 2026

EuroNet-PHL-LP1: Complete resection or low-dose chemo for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.

EuroNet-PHL-LP1: Complete resection or low-dose chemo for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.

Journal: Blood advances

Published: January 16, 2026

EuroNet-PHL-LP1: complete resection or low-dose chemotherapy for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.

EuroNet-PHL-LP1: complete resection or low-dose chemotherapy for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.

Journal: Blood advances

Published: January 16, 2026

Showing 1-12 of 472

Last Updated: 09/26/2026